ATE510013T1 - Verfahren und verwendungen von linker enthaltenden polypeptidliganden - Google Patents
Verfahren und verwendungen von linker enthaltenden polypeptidligandenInfo
- Publication number
- ATE510013T1 ATE510013T1 AT05759242T AT05759242T ATE510013T1 AT E510013 T1 ATE510013 T1 AT E510013T1 AT 05759242 T AT05759242 T AT 05759242T AT 05759242 T AT05759242 T AT 05759242T AT E510013 T1 ATE510013 T1 AT E510013T1
- Authority
- AT
- Austria
- Prior art keywords
- binding
- molecule
- affinity
- target
- site
- Prior art date
Links
- 229920001184 polypeptide Polymers 0.000 title abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 2
- 239000003446 ligand Substances 0.000 title 1
- 102000004190 Enzymes Human genes 0.000 abstract 1
- 108090000790 Enzymes Proteins 0.000 abstract 1
- 102000035195 Peptidases Human genes 0.000 abstract 1
- 108091005804 Peptidases Proteins 0.000 abstract 1
- 239000004365 Protease Substances 0.000 abstract 1
- 230000023555 blood coagulation Effects 0.000 abstract 1
- 238000006243 chemical reaction Methods 0.000 abstract 1
- 230000003111 delayed effect Effects 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 238000007423 screening assay Methods 0.000 abstract 1
- 230000000087 stabilizing effect Effects 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
- G01N33/542—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with steric inhibition or signal modification, e.g. fluorescent quenching
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/66—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/37—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi
- C07K14/39—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi from yeasts
- C07K14/40—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi from yeasts from Candida
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Biophysics (AREA)
- Food Science & Technology (AREA)
- Mycology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Nanotechnology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Genetics & Genomics (AREA)
- Medical Informatics (AREA)
- Epidemiology (AREA)
- General Engineering & Computer Science (AREA)
- Crystallography & Structural Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US58170304P | 2004-06-23 | 2004-06-23 | |
| PCT/CA2005/000951 WO2006000081A1 (en) | 2004-06-23 | 2005-06-20 | Polypeptide ligands containing linkers |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE510013T1 true ATE510013T1 (de) | 2011-06-15 |
Family
ID=35781537
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT05759242T ATE510013T1 (de) | 2004-06-23 | 2005-06-20 | Verfahren und verwendungen von linker enthaltenden polypeptidliganden |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US8063018B2 (de) |
| EP (1) | EP1766011B1 (de) |
| AT (1) | ATE510013T1 (de) |
| CA (1) | CA2571815A1 (de) |
| WO (1) | WO2006000081A1 (de) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT1737889E (pt) | 2004-10-19 | 2010-12-13 | Lonza Ag | Método para síntese de péptidos em fase sólida |
| WO2010027642A2 (en) * | 2008-09-04 | 2010-03-11 | Arizona Board Of Regents | Selecting for cooperatively interacting molecules |
| WO2010135277A2 (en) * | 2009-05-18 | 2010-11-25 | Brown University | Cyclic-glur6 analogs, methods of treatment and use |
| WO2011159913A2 (en) * | 2010-06-16 | 2011-12-22 | The Trustees Of Dartmouth College | Magnetic particle heating system and method for occlusion of the fallopian tube |
| CA2833614C (en) * | 2011-04-20 | 2021-08-03 | National Research Council Of Canada | Locally-active anticoagulants and anti-inflammatory agents |
| CA2888653A1 (en) * | 2012-10-19 | 2014-04-24 | National Research Council Of Canada | Derivatives of collagen-binding hairpin peptides |
| US9545383B2 (en) | 2014-04-01 | 2017-01-17 | Massachusetts Institute Of Technology | Blood clotting control |
| IL234246A0 (en) | 2014-08-21 | 2014-11-30 | Omrix Biopharmaceuticals Ltd | Stabilized thrombin |
| KR102722610B1 (ko) | 2018-02-20 | 2024-10-25 | 파보니스 다이아그노스틱 인코포레이티드. | 산화 알루미늄 표면 및 계면 분자 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1990006128A1 (en) * | 1988-12-05 | 1990-06-14 | Biogen, Inc. | Methods and compositions for inhibiting platelet aggregation |
| US5443827A (en) * | 1993-05-03 | 1995-08-22 | President And Fellows Of Harvard College | Fibrin-targeted inhibitors of thrombin |
| CA2175388A1 (en) * | 1993-10-25 | 1995-05-04 | Yasuo Konishi | Bivalent thrombin inhibitors |
| DE4404168A1 (de) * | 1994-02-10 | 1995-08-17 | Hoechst Ag | Hirudinderivate und Verfahren zu deren Herstellung |
| US6225100B1 (en) * | 1996-07-09 | 2001-05-01 | Dcv, Inc. | Arylsulfotransferase |
| AU2798599A (en) * | 1998-02-27 | 1999-09-15 | Bioelastics Research Ltd. | Injectable implants for tissue augmentation and restoration |
| AU2003201554A1 (en) * | 2002-01-11 | 2003-07-24 | National Research Council Of Canada | Quantitative ranking of transient ligand binding to target biomolecules |
| EP1597279A1 (de) | 2003-02-27 | 2005-11-23 | National Research Council Of Canada | Peptid thrombin inhibitore mit hoher blutgerinnungshemmender aktivität |
-
2005
- 2005-06-20 WO PCT/CA2005/000951 patent/WO2006000081A1/en not_active Ceased
- 2005-06-20 US US11/630,462 patent/US8063018B2/en not_active Expired - Fee Related
- 2005-06-20 AT AT05759242T patent/ATE510013T1/de not_active IP Right Cessation
- 2005-06-20 CA CA002571815A patent/CA2571815A1/en not_active Abandoned
- 2005-06-20 EP EP05759242A patent/EP1766011B1/de not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| EP1766011A1 (de) | 2007-03-28 |
| WO2006000081A1 (en) | 2006-01-05 |
| US20090105116A1 (en) | 2009-04-23 |
| EP1766011B1 (de) | 2011-05-18 |
| EP1766011A4 (de) | 2009-06-24 |
| CA2571815A1 (en) | 2006-01-05 |
| US8063018B2 (en) | 2011-11-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1545582A4 (de) | Von amyolid-beta abgeleitete diffundierbare liganden (addls), addl-ersatzstoffe, addl-bindungsmoleküle und verwendungen davon | |
| DK1503800T3 (da) | Behandling og forebyggelse af vævsskade associeret med forøget C-reaktiv-protein produktion | |
| EP1864998A3 (de) | Bindungsmoleküle | |
| ATE510013T1 (de) | Verfahren und verwendungen von linker enthaltenden polypeptidliganden | |
| HRP20230761T1 (hr) | Gdf zamke | |
| ATE440619T1 (de) | Gerinnungsfaktor-fc chimere proteine zur behandlung von hämophilie | |
| ATE555202T1 (de) | Verfahren zur lieferung von rna-interferenz und verwendungen damit | |
| WO2006023831A3 (en) | Sequential protein isolation and purification schemes by affinity chromatography | |
| JP2004521666A5 (de) | ||
| DK3085783T3 (da) | Bispecifikt antistof som substitution for funktionelle proteiner | |
| WO2008036406A3 (en) | Compositions and methods related to protein displacement therapy for myotonic distrophy | |
| DE602006020715D1 (de) | Multiplex-assays für verzweigtkettige dna | |
| WO2004093894A8 (en) | Use of b7-h3 as an immunoregulatory agent | |
| ATE485844T1 (de) | Einwegvorrichtung zur diffusion von flüchtigen substanzen | |
| BRPI0209933B8 (pt) | proteína de fusão, e, molécula de ácido nucleico | |
| ATE480643T1 (de) | Homogener nachweis von analyten | |
| DK0915974T3 (da) | Modificerede tie-2 receptor-ligander | |
| EA200870244A1 (ru) | Слитые белки rage и способы применения | |
| WO2005017205A3 (en) | Nucleic acid mapping using linear analysis | |
| WO2004082608A3 (en) | Ligands for tgf-beta binding proteins and uses thereof | |
| DE60235467D1 (de) | Emissionsarmer einkomponentige klebstoff | |
| EP1972639A3 (de) | Reagenzien zur Erkennung von Proteinphosphorylierung in Karzinom-Signalwegen | |
| EP2083018A3 (de) | Zusammensetzungen und Verfahren mit Bezug zu STOP-1 | |
| BRPI0507918A (pt) | processo para a carbonilação de compostos insaturados, composição de catalisador, e, ligando de difosfina bidentado assimétrico | |
| AU2001296830A1 (en) | Ligand based solution assay for low concentration analytes |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |